Efficacy and Safety of XXXX Intravitreal Implant for Treatment of Refractory Macular Edema Secondary to @entity2994 in Taiwan.

@entity1 @entity231 @entity2994 @entity726 @entity1103 @entity619 @entity2790
PURPOSE: To evaluate the long-term efficacy and safety of slow-release @entity619 intravitreal implant (DEX implant) in @entity1 with refractory @entity1103 ( @entity1103 ) secondary to @entity2994 ( @entity2994 ) in Taiwan. METHODS: We conducted a retrospective chart review of @entity1 with a diagnosis of @entity1103 secondary to @entity2994 who received the DEX implant at Kaohsiung Veterans General Hospital from October 2010 to February 2014. RESULTS: A total of 28 @entity1 with an average age of 60.7  11.1 years were examined. Of these @entity1 , 17 were diagnosed with branch @entity2994 (BRVO) and 11 were diagnosed with central @entity2994 (CRVO). The mean maximal change in vision from the baseline after the final injection was an improvement of 1.7  2.8 lines (equivalent to 8.5 ETDRS letters; p<0.0001). The response to the first injection was similar across both BRVO and CRVO groups, but @entity1 with BRVO showed a more favorable response than those with CRVO after the second injection. The response in @entity1 who had refractory @entity1103 after at least 3 previous interventions was similar to the whole group. Three @entity1 (10.7%) had @entity2790 (IOP) that was well controlled by IOP-lowering medications. None of these @entity1 required laser or @entity726 surgery. Five @entity1 (17.9%) exhibited @entity231 progression during the observation period. CONCLUSION: The DEX implant is an effective and safe treatment for @entity1103 , secondary to @entity2994 , including refractory @entity1103 .
